TAK1 Is a Pivotal Therapeutic Target for Tumor Progression and Bone Destruction in Myeloma

Haematologica - Italy
doi 10.3324/haematol.2019.234476
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Bone Destruction in Multiple Myeloma

Annals of the New York Academy of Sciences
GeneticsMolecular BiologyBiochemistryNeuroscienceHistoryPhilosophy of Science
2006English

FOXM1 Is a Therapeutic Target in High-Risk Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

TRAF6 Activation in Multiple Myeloma: A Potential Therapeutic Target

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2012English

YAP1 Is Essential for Tumor Growth and Is a Potential Therapeutic Target for EGFR-dependent Lung Adenocarcinomas

Oncotarget
Oncology
2017English

Melanoma Inhibitor of Apoptosis Protein (ML-IAP) Is a Target for Immune-Mediated Tumor Destruction

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2003English

TREM-1; Is It a Pivotal Target for Cardiovascular Diseases?

2018English

Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma

Cancer Research
Cancer ResearchOncology
2016English

EZH2 as a Therapeutic Target for Multiple Myeloma and Other Haematological Malignancies

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy